Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis.
文献摘要
Introduction Lebrikizumab provides lasting improvements in skin clearance and itch relief in patients with moderate-to-severe atopic dermatitis (AD). This analysis assessed long-term stability, depth of response, and flare incidence through 3 years in week 16 responders from ADvocate1 and ADvocate2 who continued maintenance lebrikizumab regimen (every 4 weeks [Q4W] or every 2 weeks [Q2W]) in the ADjoin extension study. Methods Responders achieved either an Investigator's Global Assessment (IGA) score of 0 or 1 with ≥ 2-point improvement or ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16, without rescue medication use. Long-term deep response was defined by skin and itch endpoints (3 years: IGA 0, ≥ 90% improvement from baseline in EASI [EASI 90], 100% improvement from baseline in EASI [EASI 100], absolute EASI score of ≤ 1 [EASI ≤ 1], Patient-Oriented Eczema Measure [POEM] [0, 1], POEM itch [0, 1]; 2 years: Pruritus Numeric Rating Scale [0, 1]). Stability was defined as maintaining outcomes at ≥ 80% of attended visits between week 16 and week 152. Flares were evaluated via three definitions: any rescue therapy use, high-potency topical corticosteroids or systemic intervention, or adverse events due to AD exacerbation. Results After 152 weeks of continuous treatment, 88.6% (Q4W) and 80.0% (Q2W) of week 16 responders maintained EASI 90, while 64.3% (Q4W) and 68.8% (Q2W) maintained EASI 100. Most patients achieving EASI 90 or EASI 100 at week 16 maintained stable responses through week 152 (Q4W: 77.8% and 57.9%; Q2W: 81.1% and 63.6%, respectively). Among stable EASI 75 responders (Q4W), 72.8% did not experience any flare through week 152, with an incidence rate of 0.19 flares per patient-year (~1 flare every 5 patient-years). Improvements in itch outcomes were sustained over time and followed patterns similar to those observed for skin responses. Conclusions Continuous lebrikizumab treatment through 3 years provided stable disease control in skin and itch symptoms, with infrequent flares experienced by week 16 responders with moderate-to-severe AD. Trial registration ClinicalTrials.gov NCT04146363, NCT04178967, and NCT04392154.